Enterprise AI Translation for FDA Submissions: What Life Sciences Teams Need to Know

Why Translation Speed Is Now a Strategic Bottleneck

Getting a drug or medical device through FDA review has always been a race against the clock. But a growing body of evidence shows that the bottleneck is no longer just scientific — it's linguistic and administrative. Research commissioned by Genpact found that 72% of senior life sciences executives rank regulatory affairs timelines among their top three challenges, and 50% of team time is consumed by administrative tasks rather than scientific work.

For companies operating across multiple markets, every FDA submission involving foreign-language documents — clinical trial data from overseas sites, manufacturing records from global facilities, adverse event reports from multilingual patient populations — must be translated into English with certified accuracy. That requirement creates a massive, repetitive translation workload that directly impacts time-to-market.

Enterprise AI translation is emerging as a practical response: not to replace human expertise, but to compress the time and cost of producing submission-ready English documents at scale.

What the FDA Actually Requires for Translated Documents

Before evaluating any technology, regulatory teams need to understand the FDA's non-negotiable translation standards:

• English-only submissions: All documents submitted to the FDA must be in English. Foreign-language originals must be accompanied by certified English translations.
• Complete fidelity: Translations must precisely reflect the source document — no omissions, simplifications, or interpretive additions.
• Qualified translators: For GLP study reports, translators must have documented education, training, or experience in both English and the source language, plus familiarity with medical and scientific documents.
• Certification and traceability: A signed, dated certification statement must accompany each translation. Organizations must maintain records of translator qualifications and consistent version control.
• Risk-based scrutiny: The FDA applies a risk-based framework — critical safety information (informed consent forms, labeling, adverse event reports) receives higher translation scrutiny than lower-risk content.

These requirements don't change because AI is involved. The FDA's focus remains squarely on the quality, accuracy, and completeness of the final translated text, regardless of what tools produced the initial draft.

How AI Translation Fits into the Regulatory Workflow

Enterprise AI translation for FDA submissions typically operates as a multi-layered pipeline rather than a single tool. Here's how leading organizations are structuring the workflow:

Neural Machine Translation (NMT) as the First Pass

Modern NMT engines trained on millions of medical and regulatory documents can produce high-quality initial drafts for many standard document types: clinical trial protocols, case report forms, investigator's brochures, and patient information leaflets. When paired with translation memories and client-specific glossaries, NMT ensures consistent terminology across thousands of pages — a critical requirement for regulatory compliance.

Generative AI for Context and Adaptation

Large language models add a layer of contextual understanding that traditional NMT lacks. They can adapt industry-specific jargon to the appropriate register, improve readability of patient-facing materials, and flag ambiguous source text that might need clarification before translation. For multilingual localization — translating a single submission package into multiple languages for different markets — GenAI can significantly reduce turnaround time while maintaining localized readability.

Human Post-Editing as the Quality Gate

This is where regulatory compliance is won or lost. Expert linguists specializing in life sciences content perform post-editing on AI-generated drafts, checking for:

• Terminological accuracy against FDA-preferred language
• Omissions or additions introduced by the translation engine
• Consistency across related documents in the same submission package
• Cultural and contextual appropriateness for patient-facing materials

The ISO 18587 standard for post-editing of machine translation output provides an auditable framework for this process. Organizations that combine AI speed with ISO-certified human review are best positioned to meet both FDA requirements and internal efficiency targets.

Compliance Frameworks That Matter

Deploying enterprise AI translation in a regulated environment requires attention to several overlapping compliance domains:

Companies evaluating AI translation vendors should verify that these certifications and compliance capabilities are documented and auditable — not just claimed in marketing materials. Platforms like ZettaLab are addressing this gap by integrating an AI Translation Agent directly into the R&D workspace, so IND, NDA, and BLA documentation workflows stay within a single secure environment — reducing the need to move sensitive regulatory content between disconnected tools.

The FDA's Own AI Transformation — and What It Means for Submissions

In a development with direct implications for translation strategy, the FDA itself is undergoing an aggressive AI transformation. In May 2025, the agency announced plans to deploy generative AI enterprise-wide by June 2025, following the completion of its first AI-assisted scientific review pilot.

The pilot, conducted by FDA's Center for Drug Evaluation and Research (CDER), used an internal AI assistant named "Elsa" to review documents related to Investigational New Drug applications. According to Jinzhong Liu, Deputy Director of the Office of Drug Evaluation Sciences, the technology enabled scientific review tasks "in minutes that used to take three days."

FDA Commissioner Martin Makary framed the initiative as a way to "reduce the amount of non-productive busywork that has historically consumed much of the review process." The agency has established a new Center of Excellence and AI Governance Board to oversee the rollout.

For life sciences companies, this signals a clear direction: submissions formatted for AI compatibility — structured, machine-readable, consistently translated — will move through review faster. Companies that continue relying on manual, inconsistent translation processes risk creating friction at the exact point where the FDA is trying to accelerate.

Common Risks and How to Mitigate Them

Enterprise AI translation is powerful, but it carries specific risks in a regulatory context:

Hallucinations

AI systems can generate convincing but factually incorrect text. In a regulatory submission, a single hallucinated dosage instruction or fabricated safety claim could trigger a clinical hold. Mitigation: every AI-generated translation must undergo line-by-line human review against the source document.

Terminology Inconsistency

Without proper glossary management, AI tools may translate the same term differently across documents in a single submission package. Mitigation: enforce centralized terminology databases and translation memories across all projects.

Data Security Exposure

Submitting proprietary clinical data to public AI platforms creates confidentiality risks. Some public LLMs retain user-submitted content. Mitigation: use enterprise-grade, on-premise or private-cloud translation platforms with documented data handling policies and BAA agreements.

Bias in Training Data

AI models trained on biased datasets may mishandle low-frequency pharmacological terminology or produce culturally inappropriate medical translations. Mitigation: domain-specific model fine-tuning on curated life sciences corpora, combined with expert human review.

Building the Business Case

For regulatory affairs leaders evaluating enterprise AI translation, the business case extends beyond cost per word. Consider the full impact on submission timelines:

• Faster IND and NDA submissions: AI-assisted translation can reduce document turnaround from weeks to days, directly compressing the pre-submission timeline.
• Consistent global submissions: When a drug is filed in the US, EU, and Japan simultaneously, AI translation with centralized glossaries ensures terminological consistency across all dossiers.
• Reduced regulatory queries: Inaccurate translations are a leading cause of FDA information requests. Higher-quality translations reduce back-and-forth, saving months of review time.
• Scalable pharmacovigilance: AI translation enables faster processing of multilingual adverse event reports, supporting compliance with strict reporting deadlines (e.g., 15-day expedited reports).

The organizations that will navigate FDA submissions most effectively in the coming years are those that treat AI translation not as a cost-cutting experiment, but as a regulated, quality-controlled capability that sits alongside clinical data management and regulatory writing as a core submission function. When translation is embedded in the same platform where experimental data is recorded and documented — as ZettaLab does by connecting its GLP-ready electronic lab notebook (ZettaNote) with the AI Translation Agent — teams reduce handoff errors and maintain a single source of truth from bench to filing.

Key Takeaways

• The FDA does not ban AI-assisted translation, but it holds translated content to the same accuracy and certification standards as human-only translations.
• A hybrid model — AI for speed and volume, certified human linguists for accuracy and compliance — is the current industry best practice.
• The FDA's own AI deployment signals that structured, machine-readable submissions will increasingly be the norm.
• Compliance with ISO 17100, ISO 18587, 21 CFR Part 11, and HIPAA/GDPR is essential for any enterprise AI translation platform handling regulatory content.
• Investing in terminology management, secure infrastructure, and expert post-editing workflows is not optional — it's the difference between a clean submission and a regulatory hold.